UICC | Leading the global fight against cancer

Time 2021-04-28 09:08:42

Web Name: UICC | Leading the global fight against cancer

WebSite: http://www.uicc.org

ID:172822

Keywords:

the,Leading,UICC,

Description:

About UICC"The Union for International Cancer Control (UICC) unites and supports the cancer community to reduce the global cancer burden, to promote greater equity, and to ensure that cancer control continues to be a priority in the world health and development agenda."Read more Become a memberAre you interested in joining a dynamic network of over 1,000 members that share a passion to eliminate cancer as a life-threatening disease for future generations. Join us today:Apply for membership Become a partner Through our proven track record of success, UICC is able to bring influential stakeholders together, and we invite you to be part of this journey and help us drive change globally. Learn more International Cancer Control Partnership (ICCP)The ICCP Portal is a one-stop shop for cancer prevention and control planning. It hosts selected resources on cancer control like toolkits, multimedia campaigns or background data.Learn moreUnion for International Cancer ControlUICC"The Union for International Cancer Control (UICC) unites and supports the cancer community to reduce the global cancer burden, to promote greater equity, and to ensure that cancer control continues to be a priority in the world health and development agenda."Become a member How COVID-19 vaccines could help put cancer care back on track Dany Habr, Chief Medical Officer, Pfizer Oncology, shares his perspective on what the roll-out of COVID-19 vaccines could mean for the cancer community and the important lessons that Pfizer has learned throughout the pandemic. Adapting HPV vaccine programmes in the COVID-19 pandemic When the COVID-19 pandemic first hit and schools closed, girls in Uganda weren’t only missing out on in-person learning but also access to HPV vaccination. An inside look from Tara Newton at PATH on the occasion of World Immunization Week. Access to radiotherapy: keeping the focus and conversation during COVID-19 Radiotherapy plays an important role in improving chances of survival for cancer patients but is not widely available in low-resource settings. Dr Mushonga and Dr Scott look at some of the barriers to access and how they can be overcome. The role of palliative care in cancer care Dr Cary Adams of UICC speaks with Dr Stephen Connor of WHPCA on the importance of palliative care for people living with cancer. This is the first in a new series of UICC Conversations where high-level experts provide insight into key aspects of cancer care and related issues. Mobilising support to reduce inequities and improve outcomes in women s cancers This International Women’s Day on 8th March, WHO builds on the momentum generated by the cervical cancer elimination strategy with a new initiative on breast cancer, an action supported by UICC’s own investment in women cancers. Cancer and COVID-19 resources As health systems in many countries become overwhelmed by COVID-19, UICC is keenly aware of the immense challenges this situation creates for cancer patients and caregivers. Find our list of resources on cancer and COVID-19 here (regular updates). 27 April 2021 Secondhand smoke exposure and oral cancer risk: a systematic review and meta-analysis A new study has shown that a non-smoker who lives in a home where someone smokes is at a 51% higher risk of developing mouth cancer than if they lived in a smoke-free home. Source: British Medical Journal 26 April 2021 Build health systems where conventional services cannot reach Focusing on the “three Cs” of health delivery — community-led, connectivity, and collaborations — can help to build more flexible health systems for hard-to-reach populations in LMICs. Source: Foresight 26 April 2021 Existential distress in patients with advanced cancer and their caregivers: study protocol of a longitudinal cohort study Despite the strong potential to alleviate existential distress through psychosocial interventions, existential distress and its impact on healthcare outcomes have not yet been studied systematically.  Source: British Medical Journal Close partner description American Society for Clinical Pathology (ASCP) The American Society for Clinical Pathology (ASCP) is the world’s largest professional membership organisation for pathologists and laboratory professionals. In addition to their educational and certification missions around the world, they maintain a very active global health delivery program focused on laboratory strengthening in all aspects. Through their 10 year + work with PEPFAR, they have improved HIV-related testing and access in ~20 countries, trained more than 3000 individuals, and continue to deliver innovated diagnostics their partners. The Cancer Diagnostics and Treatment in Africa Initiative, created and led by ASCP, aims for 100% access to diagnostics for patients with cancer through on-site assessment, implementation planning, and, ultimately, connectivity to experts around the world through telepathology. With more than 100,000 members, the society’s influence has guided the application and evolution of the pathology and laboratory medicine specialty since 1922. ASCP is leading the way in global health pathology. Close partner description Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Close partner description Astellas The Astellas Group aims to become a R D-driven global pharmaceutical company contributing to people’s health. Astellas’s business philosophy has three elements — raison d'être, mission and beliefs. This business philosophy expresses the company’s aim to contribute to the health of people around the world through the provision of highly effective and trustworthy pharmaceuticals, while continuously increasing the Company's enterprise value. Close partner description Bristol-Myers Squibb (BMS) Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases. Close partner description Cancerfonden Founded in 1951 to support cancer research, the Swedish Cancer Society is an independent non-profit organization with the vision of finding cures for cancer. The overall aim of the Society is to achieve a higher survival rate and a reduction in the incidence of cancer. Their main task is to raise and distribute money for cancer research. As one of the largest financiers of cancer research in Sweden, the Swedish Cancer Society essentially acts as a national research council. Thanks to the organization’s extensive knowledge about cancer, the Swedish Cancer Society is also active in areas such as public opinion and spreading knowledge about cancer, as well as results of cancer research. Close partner description China Anti-Cancer Association (CACA) Established in 1984, the China Anti-Cancer Association (CACA) is a non-government and non-profit organisation with a mission to unite people involved in all branches of oncology with a shared interest in fighting cancer. CACA is dedicated to improving cancer control in China through increasing the survival rates, and decreasing the incidence and mortality rates of cancer. CACA plays an important role in promoting academic exchange, organising public education, establishing collaboration with international cancer societies, and providing data and advice to the Chinese government for making strategies and policies on cancer control. The branches consist of 45 professional societies, 47 full membership organisations, and 30 local anti-cancer associations with a total membership exceeding 47,000. Close partner description CUBEBIO CUBEBIO is a biomedical company, headquartered in Seoul, South Korea, dedicated to researching and developing cancer diagnostic biomarkers and in vitro diagnostics. The company also possesses more than 30 patents in relation to cancer diagnosis. Since its establishment, CUBEBIO commits itself to the continuous research and development for global health improvements by detecting cancer early through self-diagnosis by means of urine as a specimen. CUBEBIO’s urine-based self-diagnostic technology enables anyone to check their cancer status fast, accurately, economically, and frequently, thereby making early screening possible and, in the case of cancer patients, allowing them to monitor their cancer for progression or recurrence.CUBEBIO aims to enter world markets by fostering close working relations with cancer societies, foundations, and research centers in each and every country. By doing so, CUBEBIO works towards creating a new culture where complex cancer diagnostic procedure becomes simpler and more accessible by self-diagnosis, regardless of time and place, and thus emerges as a new global leader in the healthcare industry. Close partner description DKG Krebsgesellschaft The German Cancer Society (DKG) is the largest scientific and specialist oncology company in Germany with headquarters in Berlin. They are engaged in cancer care on the basis of evidence-based medicine, interdisciplinary and consequent quality standards. In total, DKG has about 7600 members, organised in 24 working groups, 16 regional cancer societies and 34 sponsors from research-based pharmaceutical industries, scientific publishers and health insurances. Since cancers need to be cross-treated and researched, their members are not only medical doctors of all sections, but also basic researchers, medical technical assistants, nurses, psychologists and other professionals who work on cancer.DKG specialises in certification of oncological care institutions, development of clinical practice guidelines, coordination of guidelines in the framework of the German Guideline Program of Oncology (GGPO), development and transfer of oncological knowledge, and improvement of information given to patients. Close partner description Fondation Philantropia An umbrella foundation associated with the bank Lombard Odier and a registered charity, Fondation Philanthropia has been helping its donors bring their philanthropic initiatives to fruition in all areas of social responsibility since 2008. It provides philanthropic expertise and support to those who wish to develop a philanthropic project in line with their background, desires and ambitions. The Foundation offers its donors a legal, financial and philanthropic framework for made-to-measure projects.The Foundation now operates more than 20 personal funds and has received over 115 million Swiss francs in donations, of which over a third has already been distributed or committed. Its donors have been highly committed to the fight against cancer, with over 15 million spent on the cause. Close partner description Friends of Cancer Patients (FOCP) Friends of Cancer Patients UAE (FoCP UAE) charity is a non-profit organisation, founded in September 1999 under the directives and patronage of Her Highness Sheikha Jawaher Bint Mohammed Al Qasimi, Wife of the Ruler of Sharjah, United Arab Emirates (UAE).FoCP UAE provides a broad spectrum of support for its patients including financial support, which entails covering treatment expenses for chemotherapy, radiation and other needed medications, in addition to expenses for investigative and surgical procedures including bone marrow transplants and prosthetic limbs. FoCP UAE provides transportation and food allowance for underprivileged cancer patients and facilitates sending patients abroad for specialised treatment. FoCP UAE also provides moral support, offering cancer patients and their families psychological consultations and Hajj and Umrah services. Close partner description ICON Group Icon Group is a leading provider of cancer care across Australasia. Icon believes in bringing the best cancer treatment possible, to as many people as possible, as close to home as possible. They do this through leveraging the latest technology, collaborating with like-minded partners and investing in outstanding people. Close partner description Institut National du Cancer The French National Cancer Institute (INCa) is the preeminent health and science agency in charge of cancer control in France, created under the Public Health Act of 9th August 2004. It reports to the ministries for Health and for Research.The Institute is a public interest grouping (GIP) which brings together State representatives, charities, health insurance funds, research organisations and hospital federations. These stakeholders share a common goal of reducing the incidence of avoidable cancers and the number of cancer deaths, improving the quality of life of people with cancer during and after their illness, and reducing inequalities related to cancer.The Institute provides an integrated approach encompassing all cancer-control dimensions (health, scientific, social and economic) and areas of intervention (prevention, screening, care and research) for the benefit of patients and their relatives.To catalyse progress, the INCa acts as an interface with patients, their friends and families, the healthcare system users, general public, healthcare professionals, researchers, experts and decision-makers. Capacity Building Close partner description MSD (Merck Co) For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases.  MSD is a trade name of Merck Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. Close partner description National Cancer Institute (NCI) The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. Close partner description Novartis Oncology Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets. Close partner description Pfizer At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Close partner description Roche Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. Close partner description Sanofi Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life. Close partner description UICC Japan The Japan National Committee for UICC is a group of Japanese organisations that are members of the Union for International Cancer Control (UICC), gathered to support the UICC to strive to realise the World Cancer Declaration. Currently UICC-Japan is composed of 29 full Japanese UICC members, including major cancer specialists in Japan, cancer centres, research institutes, research funds, hospitals and cancer associations.Are you organising a cancer-related event and would like to feature it in our events section?Suggest an event

TAGS:the Leading UICC 

<<< Thank you for your visit >>>

The Union for International Cancer Control (UICC) unites and supports the cancer community to reduce the global cancer burden, to promote greater equity, and to ensure that cancer control continues to be a priority in the world health and development agenda.

Hot Websites